SecBot SecBot
SECBOTREPLAY Home › Report › ANIP

ANIP · ANI Pharmaceuticals announced the publication of NEW DAY clinical trial…

ANI Pharmaceuticals, Inc. · PRESS-RELEASE filed Apr 7, 2026 at 06:50 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 7, 2026 at 06:50 ET

ANI Pharmaceuticals announced the publication of NEW DAY clinical trial results for ILUVIEN in the journal Ophthalmology, reinforcing clinical data for its use in diabetic macular edema (DME). This is a scientific validation rather than a new clinical or commercial development.

  • Results from the NEW DAY Phase 4 trial of ILUVIEN for diabetic macular edema were published in Ophthalmology, a peer-reviewed journal.
  • The trial results were previously disclosed in July 2025; this press release highlights peer-reviewed publication.
  • ILUVIEN is indicated for DME patients previously treated with corticosteroids without significant intraocular pressure rise.
  • Safety data show high incidence of cataract (82%), intraocular pressure elevation (34% had ≥10 mm Hg increase), and need for IOP-lowering treatment (38%).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access